Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Hengrui Pharma and Kailera Therapeutics have announced positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide (HRS9531 tablet; KAI-9531-T), a GLP-1/GIP receptor dual agonist peptide, in adults living with obesity in China.

As described in a February 10, 2026, press release, participants receiving oral ribupatide demonstrated a mean weight reduction from baseline of up to 12.1% at 26 weeks based on the efficacy estimand with no observed plateau in weight loss, and vomiting was reported in ≤ 11.4% of participants taking oral ribupatide.

“The Hengrui Phase 2 clinical trial results mark an important milestone in the expansion of our ribupatide franchise. We believe oral ribupatide could help to address the diverse needs of people living with obesity or overweight and meet patients wherever they are in their treatment journey,” Scott Wasserman, MD, Chief Medical Officer of Kailera, said in a statement. “These positive data suggest a potentially game-changing clinical profile for an oral obesity therapy, and we look forward to initiating a Phase 2 trial later this year. Concurrently, we intend to build upon the comprehensive injectable ribupatide data with the Phase 3 KaiNETIC program with the goal of rapidly and efficiently bringing more options to patients.”

Ribupatide is a GLP-1 receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral tablet for the treatment of obesity and overweight. Once-weekly injectable ribupatide has been studied in > 2500 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted a marketing authorization application to the National Medical Products Administration in China for long-term weight management in adults.

In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture, and commercialize its portfolio of innovative GLP‑1 therapeutics, including ribupatide. With these rights, Kailera is currently evaluating injectable ribupatide for the treatment of obesity in the KaiNETIC global phase 3 clinical program.

The HRS9531-T-201 clinical trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial conducted by Hengrui in China to evaluate the efficacy and safety of oral ribupatide in adults ≥18 years of age living with obesity, defined as BMI ≥ 28 kg/m2, and without type 2 diabetes.

The study enrolled 166 participants who were randomly assigned in equal ratio to receive once-daily oral ribupatide 10 mg, 25 mg, 50 mg, or placebo. Participants followed a simple titration schedule, reaching the doses of 10 mg and 25 mg at week 4, and 50 mg at week 8. The primary objective was to evaluate the effect of oral ribupatide versus placebo on body weight at 26 weeks.

Based on the efficacy estimand at week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg) from baseline, with no observed plateau in weight loss, compared to 2.3% with placebo. Based on the treatment policy estimand at week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg) from baseline, with no observed plateau in weight loss, compared to 2.1% with placebo.

Additionally, at the 25 mg dose, 59.1% of participants achieved at least 10% weight loss, and 38.6% of participants achieved at least 15% weight loss at week 26. At the 50 mg dose, 52.5% of participants achieved at least 10% weight loss, and 37.5% of participants achieved at least 15% weight loss at week 26.

Results showed wral ribupatide demonstrated a favorable safety and tolerability profile, with most treatment-emergent adverse events (TEAEs) being mild to moderate and gastrointestinal (GI)-related. Rates of vomiting were 2.4% at 10 mg, 11.4% at 25 mg, and 7.5% at 50 mg while nausea was 11.9% at 10 mg, 22.7% at 25 mg, and 20.0% at 50 mg, consistent with the results of the trials previously conducted by Hengrui in China. No permanent treatment discontinuations or down-titrations due to nausea, vomiting, diarrhea, or constipation were reported in participants taking oral ribupatide.

“We are pleased to share these positive topline Phase 2 results for oral ribupatide. These data highlight the potential to deliver a differentiated oral medication for the treatment of obesity," Zi Ye, Senior Medical Director, Metabolic Diseases, Clinical Development, Hengrui Pharma, said in a statement. “We plan to rapidly advance to a Phase 3 clinical trial in China, bringing us a step closer to a potential new oral treatment option for people living with obesity.”

In addition to Hengrui’s plans to advance oral ribupatide to a phase 3 clinical trial for the treatment of obesity in China, Kailera plans to initiate a global phase 2 clinical trial in 2026. Hengrui additionally described intentions to share the full oral ribupatide phase 2 clinical trial data at an upcoming scientific conference.

Kailera Therapeutics. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide. February 10, 2026. Accessed February 10, 2026. 

https://www.kailera.com/press-release/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide/

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531). January 12, 2026. Accessed February 10, 2026. 

https://www.kailera.com/press-release/kailera-therapeutics-announces-first-participants-randomized-in-kainetic-global-phase-3-clinical-program-of-glp-1-gip-receptor-dual-agonist-ribupatide-kai-9531/

Articles

Hengrui’s phase 2, randomized, double-blind, placebo-controlled trial in 166 Chinese adults with obesity (BMI ≥28 kg/m²) without type 2 diabetes showed once-daily oral ribupatide produced clinically meaningful weight loss at 26 weeks. Mean reductions reached 12.1% with 25 mg and 50 mg (efficacy estimand) versus ~2.3% with placebo, without an observed plateau. GI adverse events were mostly mild-to-moderate; vomiting occurred in ≤11.4% and no permanent discontinuations or down-titrations occurred due to GI toxicity. Phase 3 plans are advancing in China, with global development ongoing.

Positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide highlight weight loss of up to 12.1% with no observed plateau at 26 weeks.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Rob Myers, MD | Image Credit: Drug Discovery & Development

TLC-2716, an oral, liver-targeted liver X receptor (LXR) inverse agonist in development by OrsoBio, has met its primary efficacy endpoint in patients with 

metabolic dysfunction-associated steatotic liver disease (MASLD)

Announced on February 10, 2026, OrsoBio announced positive topline results from a phase 2a proof-of-concept study evaluating TLC-2716 in reducing fasting triglyceride and improving remnant cholesterol and hepatic fat. This was a randomized, double-blind, placebo-controlled study including once-daily oral doses of TLC-2716 6 mg or 12 mg for 4 weeks.

“These Phase 2a data provide compelling clinical validation of LXR inverse agonism as a differentiated therapeutic strategy for severe metabolic disorders,” Rob Myers, MD, chief medical officer and head of development for OrsoBio, said in a statement. “The substantial reductions in triglycerides, remnant cholesterol, and other atherogenic lipids – along with improvements in liver fat and a favorable safety profile – support the potential of TLC-2716 to become a meaningful therapeutic option for patients with diseases driven by excessive lipid production, including SHTG, [metabolic dysfunction-associated steatohepatitis (MASH)], and elevated remnant cholesterol.”

TLC-2716 is an oral, small-molecule, liver-targeted, inverse LXR agonist, designed to modulate key pathways connected to lipid homeostasis. The drug targets de novo lipogenesis, lipoprotein clearance, and intestinal lipid absorption. Liver X receptors are oxysterol-activated nuclear hormone receptors, typically modulating plasma triglycerides and cholesterol via several complementary mechanisms.

In total, the study included a 4-week screening period, a 4-week treatment period, and a 2-week follow-up period. Investigators included patients with a body mass index (BMI) ≥28 kg (61.7 lb)/m2 and a fasting triglyceride ≥350 mg/dL without diabetes or with diabetes and HbA1c <9.5% at screening. Additionally, patients were required to have a diagnosis of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) within 5 years of screening based on hepatic imaging and be normotensive or without uncontrolled hypertension, which was defined as systolic blood pressure >155 mmHg and/or diastolic blood pressure >90 mmHg at screening.

Patients were excluded if they had HbA1c ≥9.5% at screening, weight loss >5% during the 90 days before screening, a positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C antibody, or a medical history of liver disease other than NAFLD/NASH. Additionally, those with unstable cardiovascular disease, a history of intestinal resection or malabsorptive conditions, or the presence of severe peptic ulcer, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions at screening, among other criteria.

A total of 30 adults with overweight and fasting triglycerides ≥350 mg/dL with evidence of MASLD via imaging or biopsy were enrolled. These patients were then randomly assigned to TLC-2716 6 mg, 12 mg, or matched placebo. The primary endpoints were the relative percent change in fasting triglycerides at week 4 and incidence of treatment-emergent adverse events. Both were measured up to day 28 of the study.

Ultimately, TLC-2716 demonstrated consistent improvements across total cholesterol, non-HDL cholesterol, and VLDL cholesterol. Investigators determined that these data support continued evaluation. These data follow a recent publication of first-in-human phase 1 clinical data, which demonstrated clinical and mechanistic validation of TLC-2716 across human genetics and organoid systems.

“We look forward to presenting a comprehensive dataset at a future scientific conference to provide a more detailed characterization of the therapeutic profile of TLC-2716,” Myers said. “These results support continued development of TLC-2716 across multiple severe metabolic disorders, which collectively affect millions of patients worldwide.”

OrsoBio, Inc. OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease. 

. February 10, 2026. Accessed February 10, 2026. 

https://www.businesswire.com/news/home/20260210425918/en/OrsoBio-Announces-Positive-Topline-Phase-2a-Data-for-LXR-Inverse-Agonist-TLC-2716-in-Severe-Hypertriglyceridemia-and-Metabolic-Liver-Disease

OrsoBio, Inc. Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD. ClinicalTrials.gov Identifier: NCT06564584. Updated April 3, 2025. Accessed February 10, 2026. 

https://clinicaltrials.gov/study/NCT06564584

OrsoBio reported positive topline phase 2a proof-of-concept results for TLC-2716, an oral liver-targeted LXR inverse agonist, in severe hypertriglyceridemia with MASLD. Thirty overweight adults with fasting triglycerides ≥350 mg/dL received 6 mg, 12 mg, or placebo once daily for four weeks. Primary endpoints were percent change in fasting triglycerides at week 4 and treatment-emergent adverse events. Treatment produced substantial triglyceride and remnant cholesterol reductions, broader atherogenic lipid improvements, decreased hepatic fat, and a favorable safety profile, supporting continued development.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

TLC-2716 Achieves Primary Endpoints in Phase 2a Trial in Patients With SHTG and MASLD

Atopic Dermatitis and Pruritus Management Updates for 2026, With Raj Chovatiya, MD, PhD

Raj Chovatiya, MD, PhD, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School, spoke in an interview with the 

 conference regarding his session he had presented at the meeting.

 regarding several key takeaways from his portion of the session titled ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’ The talk focused on ways newer monoclonal antibodies, oral Janus kinase (JAK) inhibitors, and topical non-steroidal therapies are fitting into atopic dermatitis care.

 He was also asked how he personally thinks about positioning these options in real-world practice.

“I think that the new interventions and new approaches in the last handful of years are really the backbone of this in my practice,” Chovatiya said. “...Topical corticosteroids and even topical calcineurin inhibitors are really just a bridge to get me to the therapies I want to now, as opposed to being the place where I just had to wait because I really didn't want to go to broader acting immunosuppressive medications.”

In his interview, Chovatiya noted every patient can receive more highly targeted therapy options. He highlighted what he describes as the bevy of non-steroidal topical options approved in the last few years, pointing to tapinarof, ruxolitinib, and roflumilast. He also pointed to oral medications such as abrocitinib and upadacitinib. Additionally, Chovatiya highlighted biologics such as dupilumab, tralokinumab, lebrikizumab, and nemolizumab.

In the case of chronic hand eczema (CHE), topical delbocitinib is a treatment described by Chovatiya as another helpful addition to the atopic dermatitis armamentarium.

For any additional information on new options for patients in the atopic dermatitis space, view Chovatiya’s full interview above. To find out more from Maui Derm, view the 

The quotes used in this summary were edited for clarity.

Chovatiya previously reported serving as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Silverberg J, Chovatiya R, Eichenfield L. Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Honda T. A new era in atopic dermatitis treatment and evolving therapeutic strategies. Immunol Med. 2025 Sep 30:1-13. 

Videos

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Frank Gonzalez is an attending physician at Children’s Hospital Los Angeles and an assistant professor of clinical pediatrics at Keck School of Medicine of USC.

Extreme Cold Independently Associated with Pain Episodes in Pediatric Sickle Cell Disease

With rates of extreme weather events rising due to climate change, clinicians may need to take additional measures to prevent pain episodes in pediatric patients with 

, as a new study suggests severe cold temperatures are independently associated with increased risk.

The findings highlight the association between extreme weather, both hot and cold, and vaso-occlusive crises (VOC), while also suggesting a potential protective effect of higher temperatures on acute chest syndrome (ACS).

“We've known for a while that there does seem to be some sensitivity to weather changes, but a lot of the studies have been done in adult, single-center populations,” study investigator Frank Gonzalez, MD, an attending physician in the emergency department at Children’s Hospital Los Angeles, said in an interview with 

 “How do these weather-related factors affect the odds of someone coming in with health complications?”

In pediatric patients with SCD, VOC is the leading cause of emergency department visits, with 96% experiencing an episode by age 8, and as many as 60% having ≥ 1 attack per year. In total, the average stay for hospitalization with VOC is 8 days, significantly impacting pediatric patients’ quality of life. These crises can occur suddenly or be triggered by extreme cold, hard work, heat and sun, psychological factors, and deficiency of ingested fluids, according to previous research.

To address the association between weather-related exposures and odds of emergency department visits for acute complications in youth with sickle cell disease, Gonzales and investigators conducted a retrospective case crossover study.

They examined emergency department encounters at 40 US children’s hospitals from 2015 to 2020. They categorized patients as low risk or high risk based on the number of emergency department visits in the preceding year, with high-risk patients defined a priori as > 3 visits.

Investigators constructed a single-variable conditional logistic regression model to identify the odds of emergency department visit in association with weather-related exposures of temperature, heat index, and wet bulb globe temperature.

The study included a total of 48,885 emergency department visits for VOC and/or ACS in patients between 0 to 21 years of age.

Upon analysis of increased temperature, heat index, and wet bulb globe temperature among high-risk pediatric patients, investigators observed an associated increased odds of emergency department visits for VOC. In contrast, investigators observed a decreased risk for emergency department visit rates in ACS, with increased markers of heat stress or temperature exhibiting a protective effect.

Notably, there were no significant associations found for low-risk patients.

“This suggests that colder temperatures are actually a risk factor for developing acute chest syndrome, which is a very important finding,” said Gonzales. “Previous studies have thought that it's the more infectious risk factors during the colder months that are leading to the development of acute chest but we're thinking that just cold weather on its own is an independent risk factor.”

As for Gonzalez’s advice to clinicians managing this pediatric population, he recommends finding ways to prevent pain episodes by advising their patients to adapt incrementally to the extreme weather. For example, during hotter periods, patients should decrease outdoor exertional time, prioritize air conditioning, and ensure they are staying hydrated. During the colder months, clinicians should encourage patients to limit quick changes into cold temperatures by staying bundled up and staying inside during weather advisories.

Future areas of research will continue to evaluate the association between pain episodes in pediatric patients with sickle cell disease and wildfires, particularly in the Los Angeles area.

Editor’s Note: Gonzalez reports no relevant disclosures. 

Gonzalez F, Hall M, Habre R, et al. Weather-Related Exposures and Emergency Department Visits for Pediatric Sickle Cell Complications. 

. Published online 2026:10.1097/PEC.0000000000003561. doi:

https://doi.org/10.1097/PEC.0000000000003561

Jacob SA, Mueller EL, Cochrane AR, Carroll AE, Bennett WE. Variation in hospital admission of sickle cell patients from the emergency department using the Pediatric Health Information System. 

Abdo S, Nuseir KQ, Altarifi AA, Barqawi M, Ayoub NM, Mukkatash TL. Management of Sickle Cell Disease Pain among Adolescent and Pediatric Patients. 

A retrospective study found an independent association between increased pain episodes in sickle cell disease and the cold in light of increasingly extreme weather.


Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Amanda Van Jacobs, MS, RDN, LDN, CCTD, is a transplant dietician at Rush University Medical Center.

Jessica Mellinger, MD, is a senior staff hepatologist at Henry Ford Health.

Why Alcohol Recommendations in the New Dietary Guidelines Fall Short

In this segment from the latest episode of 

Liver Lineup: Updates & Unfiltered Insights

, the conversation around the newly updated US Dietary Guidelines turns to one of their most debated and most limited areas: alcohol.

While the guidelines emphasize reducing ultra-processed foods, Kimberly Brown, MD, presses the panel on whether there was a similarly clear message when it came to alcohol consumption. According to guest Jessica Mellinger, MD, the answer is yes, but only in the broadest sense.

“The message on alcohol was pretty limited,” Mellinger explains. “It was basically: drink less.”

While she says she does not disagree with that recommendation, she notes that the guidance lacks specificity and clinical nuance, particularly for patients with liver disease or conditions known to increase alcohol-related risk. Compared with prior guidelines, which defined “moderate” drinking using sex-based thresholds, the updated recommendations remove specific quantities altogether, reflecting a growing body of evidence suggesting that even low levels of alcohol consumption are associated with adverse health outcomes.

Mellinger highlights cancer risk as one of the most consistent findings in the literature, noting that alcohol is a known carcinogen with measurable associations even at low intake levels. Although certainty diminishes at lower levels of consumption, the overall trend has been toward recommending less alcohol across populations. From a hepatology standpoint, she emphasizes that this shift aligns with what clinicians increasingly see in practice.

However, Mellinger views the updated guidance less as a comprehensive directive and more as a starting point for individualized clinical conversations. In her alcohol-associated liver disease clinic, discussions often extend well beyond quantity and frequency, focusing instead on how alcohol affects a patient’s health, relationships, and quality of life.

From her perspective, there is no safe level of alcohol consumption she can ethically recommend to patients with liver disease based on the available data. Rather than offering reassurance around low-level use, she encourages clinicians to meet patients where they are, exploring motivation, readiness for change, and realistic next steps toward reduction or abstinence.

Nancy Reau, MD, adds that important at-risk populations remain absent from the public-facing guidance. Beyond pregnancy, she notes that patients who have undergone gastric bypass surgery represent another growing group for whom alcohol use carries significant risk, yet they are not explicitly addressed.

Ultimately, the panel agrees that while “drink less” may be an appropriate population-level message, it leaves critical gaps for clinicians to fill.

Editors’ Note: Relevant disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for Mellinger include GlaxoSmithKline. Van Jacobs reports no relevant disclosures.

Brooks A. New Dietary Guidelines Draw Criticism For High Fat Dairy, Protein Recommendations. HCPLive. January 8, 2026. Accessed February 9, 2026. 

https://www.hcplive.com/view/new-dietary-guidelines-draw-criticism-high-fat-dairy-protein-recommendations

AASLD. AASLD Raises Concern Over Removal of Evidence-Based Alcohol Guidance in 2025–2030 Dietary Guidelines for Americans. January 9, 2026. Accessed February 9, 2026. 

https://www.aasld.org/aasld-raises-concern-over-removal-evidence-based-alcohol-guidance-2025-2030-dietary-guidelines

In this segment of a Liver Lineup episode, experts discuss where the new US Dietary Guidelines miss the mark for alcohol recommendations.

Auchus and DeFronzo describe the underuse of hypercortisolism screening in primary care and outline a straightforward, clinically pragmatic approach to the overnight 1-mg dexamethasone suppression test and subsequent workup.

Video Series

Special Reports

Screening in Primary Care: When and How to Use the Overnight Dexamethasone Suppression Test

In this introductory segment, Richard Auchus, MD, and Ralph DeFronzo, MD, frame hypercortisolism as an underrecognized driver of difficult-to-control type 2 diabetes, hypertension, and osteoporosis, challenging the traditional view of Cushing syndrome as a rare disorder.

Rethinking “Rare” Cushing Syndrome: Hypercortisolism in Difficult-to-Control Diabetes

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Healthcare professionals discuss individualized approaches to second-line therapy for liver disease, considering patient age, fibrosis, and insurance challenges.

How Special Populations and Disease Risk Impact Treatment Assessment in PBC

Experts discuss first-line treatments for Primary Biliary Cholangitis, emphasizing the importance of monitoring and patient compliance for effective management.

Experts Review the First- and Second-Line Treatment Options for PBC

Examine adherence challenges, specialty pharmacy support, and emerging precision medicine approaches in pediatric atopic dermatitis and psoriasis.


Adherence, Specialty Pharmacies, and the Future of Precision Pediatric Care

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

HCPLive 5 Stories in Under 5: Week of 02/01

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Emily Aman, MPH, from the University of Rochester Medical Center

In an interview, investigators Emily Aman, MPH, and Rachel White highlight why marginalized children with uncontrolled asthma rarely see specialists.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Most Marginalized Children with Uncontrolled Asthma Miss Specialist Care

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 02/01

This FDA News Month in Review provides a round-up of regulatory decisions from January 2026.

Latest News

Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial

TLC-2716 Achieves Primary Endpoints in Phase 2a Trial in Patients With SHTG and MASLD

Atopic Dermatitis and Pruritus Management Updates for 2026, With Raj Chovatiya, MD, PhD

Extreme Cold Independently Associated with Pain Episodes in Pediatric Sickle Cell Disease

Why Alcohol Recommendations in the New Dietary Guidelines Fall Short